(NASDAQ: AMPH) Amphastar Pharmaceuticals's forecast annual revenue growth rate of 4.28% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 10.43%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.27%.
Amphastar Pharmaceuticals's revenue in 2026 is $730,019,000.On average, 9 Wall Street analysts forecast AMPH's revenue for 2026 to be $32,318,202,954, with the lowest AMPH revenue forecast at $30,456,742,525, and the highest AMPH revenue forecast at $34,209,014,565. On average, 9 Wall Street analysts forecast AMPH's revenue for 2027 to be $33,799,374,164, with the lowest AMPH revenue forecast at $31,365,353,008, and the highest AMPH revenue forecast at $36,254,664,292.
In 2028, AMPH is forecast to generate $35,193,342,589 in revenue, with the lowest revenue forecast at $32,224,194,098 and the highest revenue forecast at $38,188,439,226.